Literature DB >> 3085586

Specific hemoperfusion through agarose acrobeads.

S Margel, L Marcus.   

Abstract

Agarose acrobeads were produced by encapsulating polyacrolein microspheres (acrobeads) of 0.2 micron average diameter within an agarose matrix. Crosslinked agarose acrobeads of diameters ranging from 0.5 to 0.8 mm were found to be optimal spheres for specific hemoperfusion purposes. Agarose provides the biocompatibility and mechanical strength of the agarose acrobeads. Acrobeads contain a high aldehyde-group content through which various amino ligands, i.e., proteins, antigens, antibodies, enzymes, and so on, can be covalently bound in a single step under physiological pH (or other pH). Thus, antibodies, antigens, or toxic materials may be directly removed from whole blood by hemoperfusion. During in vitro and in vivo hemoperfusion trials, the content of erythrocytes, leukocytes, and thrombocytes was essentially unaltered. Likewise, a battery of the soluble blood components (Cl-, K+, Na+, Ca2+, PO3/4-), total proteins, albumin, and C'4 component of the complement cascade, as well as the enzymes SGOT, LDH, and alkaline phosphatase, remained constant within narrow limits during the hemoperfusion procedure. The chemical and physical structure of the beads is stable; neither acrolein nor bead fragments were detected in hemoperfusion trials. Similarly, leakage of antibody bound to the agarose acrobeads into the blood is insignificant. Thus far, we have demonstrated the efficacy of the crosslinked agarose acrobeads for extracorporeal removal of "unwanted" substances from whole blood in the following systems: (a) removal of specific antigens (digoxin or paraquat removal with antidigoxin or antiparaquat antibodies bound to the acrobeads, respectively), (b) removal of specific antibody (antiBSA) removal with BSA bound to the beads), (c) removal of immune complexes (BSA-antiBSA complex removal with C1q bound to acrobeads), and (d) removal of specific metals (removal of iron with deferoxamine bound to the agarose acrobeads).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3085586     DOI: 10.1007/bf02798578

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  66 in total

1.  The use of protein-substituted nylon catheters for selective immunoadsorption in vivo.

Authors:  L R Lyle; B M Parker; C W Parker
Journal:  J Immunol       Date:  1974-08       Impact factor: 5.422

2.  Sepcific removal of in vivo antibody by extracorporeal circulation over an immunoadsorbent in gel.

Authors:  I Schenkein; J C Bystryn; J W Uhr
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

Review 3.  Clinical removal of iron.

Authors:  R Propper; D Nathan
Journal:  Annu Rev Med       Date:  1982       Impact factor: 13.739

4.  Specific removal of bovine serum albumin (BSA) antibodies in vivo by extracorporeal circulation over BSA immobilized on nylon microcapsules.

Authors:  D S Terman; T Tavel; D Petty; A Tavel; R Harbeck; G Buffaloe; R Carr
Journal:  J Immunol       Date:  1976-05       Impact factor: 5.422

5.  Idiopathic hemochromatosis, an iron storage disease. A. Iron metabolism in hemochromatosis.

Authors:  S C FINCH; C A FINCH
Journal:  Medicine (Baltimore)       Date:  1955-12       Impact factor: 1.889

6.  Iron detoxification by haemoperfusion through deferoxamine-conjugated agarose-polyacrolein microsphere beads.

Authors:  D Horowitz; S Margel; T Shimoni
Journal:  Biomaterials       Date:  1985-01       Impact factor: 12.479

7.  Correlation between clinical activity of systemic lupus erythematosus and the amounts of DNA in DNA/anti-DNA antibody immune complexes.

Authors:  C Morimoto; H Sano; T Abe; M Homma; A D Steinberg
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

8.  Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis.

Authors:  T M Chang; P Barre
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

9.  Reversal of digoxin toxicity with specific antibodies.

Authors:  D H Schmidt; V P Butler
Journal:  J Clin Invest       Date:  1971-08       Impact factor: 14.808

10.  Hemoperfusion in the management of digoxin toxicity.

Authors:  J W Smiley; N M March; E T Del Guercio
Journal:  JAMA       Date:  1978-12-15       Impact factor: 56.272

View more
  2 in total

1.  Bioreactor based on suspended particles of immobilized enzyme.

Authors:  L E Freed; G V Vunjak-Novakovic; P A Drinker; R Langer
Journal:  Ann Biomed Eng       Date:  1993       Impact factor: 3.934

2.  Kinetics of immobilized heparinase in human blood.

Authors:  L E Freed; G V Vunjak-Novakovic; H Bernstein; C L Cooney; R Langer
Journal:  Ann Biomed Eng       Date:  1993       Impact factor: 3.934

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.